Anika Therapeutics, Inc. (FRA:AKP)
Germany · Delayed Price · Currency is EUR 8.45
+0.05 (0.60%)
Last updated: Dec 2, 2025, 8:01 AM CET
Anika Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 112.81 | 119.91 | 120.79 | 113.83 | 147.79 | 130.46 | Upgrade | |
Revenue Growth (YoY) | 30.55% | -0.73% | 6.12% | -22.98% | 13.29% | 13.83% | Upgrade |
Cost of Revenue | 50.45 | 43.3 | 37.51 | 40.61 | 58.39 | 61.43 | Upgrade |
Gross Profit | 62.36 | 76.6 | 83.28 | 73.22 | 89.41 | 69.03 | Upgrade |
Selling, General & Admin | 48.33 | 55.56 | 59.93 | 51.23 | 74.1 | 56.74 | Upgrade |
Research & Development | 25.83 | 25.54 | 21.76 | 18.32 | 27.33 | 22.02 | Upgrade |
Operating Expenses | 74.16 | 81.1 | 81.69 | 69.55 | 101.42 | 78.76 | Upgrade |
Operating Income | -11.8 | -4.5 | 1.59 | 3.67 | -12.02 | -9.73 | Upgrade |
Interest Expense | - | - | - | - | -0.19 | -0.3 | Upgrade |
Interest & Investment Income | 2.37 | 2.34 | 2.31 | 0.65 | - | - | Upgrade |
EBT Excluding Unusual Items | -9.43 | -2.16 | 3.9 | 4.32 | -12.2 | -10.03 | Upgrade |
Merger & Restructuring Charges | -0.61 | -0.61 | -0.75 | - | -6.47 | -4.1 | Upgrade |
Impairment of Goodwill | - | - | - | - | - | -42.52 | Upgrade |
Asset Writedown | - | - | - | - | - | -2.44 | Upgrade |
Other Unusual Items | - | - | - | - | 21.1 | 30.47 | Upgrade |
Pretax Income | -10.03 | -2.76 | 3.16 | 4.32 | 2.43 | -28.62 | Upgrade |
Income Tax Expense | 4.23 | 6.06 | 6.6 | 2.12 | -1.71 | -4.64 | Upgrade |
Earnings From Continuing Operations | -14.27 | -8.83 | -3.44 | 2.2 | 4.13 | -23.98 | Upgrade |
Earnings From Discontinued Operations | -18.77 | -47.56 | -79.23 | -17.06 | - | - | Upgrade |
Net Income | -33.04 | -56.39 | -82.67 | -14.86 | 4.13 | -23.98 | Upgrade |
Net Income to Common | -33.04 | -56.39 | -82.67 | -14.86 | 4.13 | -23.98 | Upgrade |
Shares Outstanding (Basic) | 14 | 15 | 15 | 15 | 14 | 14 | Upgrade |
Shares Outstanding (Diluted) | 14 | 15 | 15 | 15 | 15 | 14 | Upgrade |
Shares Change (YoY) | -2.20% | 0.44% | 0.65% | -0.50% | 2.90% | -1.06% | Upgrade |
EPS (Basic) | -2.29 | -3.83 | -5.64 | -1.02 | 0.29 | -1.69 | Upgrade |
EPS (Diluted) | -2.29 | -3.83 | -5.64 | -1.02 | 0.28 | -1.69 | Upgrade |
Free Cash Flow | 0.65 | -2.33 | -7.22 | -3.08 | 3.25 | 11.44 | Upgrade |
Free Cash Flow Per Share | 0.04 | -0.16 | -0.49 | -0.21 | 0.22 | 0.80 | Upgrade |
Gross Margin | 55.28% | 63.89% | 68.95% | 64.33% | 60.49% | 52.91% | Upgrade |
Operating Margin | -10.46% | -3.75% | 1.32% | 3.22% | -8.13% | -7.46% | Upgrade |
Profit Margin | -29.29% | -47.02% | -68.44% | -13.05% | 2.80% | -18.38% | Upgrade |
Free Cash Flow Margin | 0.57% | -1.94% | -5.97% | -2.70% | 2.20% | 8.77% | Upgrade |
EBITDA | -3.67 | 3.63 | 15.81 | 18.16 | 2.3 | 3.74 | Upgrade |
EBITDA Margin | -3.25% | 3.02% | 13.09% | 15.95% | 1.56% | 2.86% | Upgrade |
D&A For EBITDA | 8.13 | 8.12 | 14.22 | 14.49 | 14.32 | 13.46 | Upgrade |
EBIT | -11.8 | -4.5 | 1.59 | 3.67 | -12.02 | -9.73 | Upgrade |
EBIT Margin | -10.46% | -3.75% | 1.32% | 3.22% | -8.13% | -7.46% | Upgrade |
Effective Tax Rate | - | - | 208.97% | 49.12% | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.